Remote State Representation in Early Psychosis
Launched by UNIVERSITY OF MINNESOTA · Sep 9, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Remote State Representation in Early Psychosis," is looking to understand how people aged 15-40 who have been diagnosed with psychotic illnesses process information about their surroundings. Researchers will compare these individuals with young adults who do not have any psychiatric diagnosis. The study involves some tests and a cognitive training program aimed at improving how participants interpret and respond to their environment.
To be eligible for this trial, participants need to be between the ages of 18 and 30 and have a diagnosis of conditions like schizophrenia or schizoaffective disorder. They should also be able to communicate in English and have been living without any psychiatric hospitalizations for at least a month. Participants will need access to a computer and the internet, and they will be asked to share their contact information for a healthcare provider. This study is currently recruiting participants, and it offers a chance to contribute to important research while also receiving cognitive training that could be beneficial.
Gender
ALL
Eligibility criteria
- • INCLUSION CRITERIA
- All Participants:
- • 1. Between the ages of 18-30 at the time of screening
- • 2. Fluent in spoken and written English, in that the participant learned to speak English before the age of 12 or is able to demonstrate fluency in conversation with study staff
- • 3. Has an outpatient status and no hospitalization for psychiatric reasons for at least 1 month prior to participant
- • 4. Has access to a computer with internet connection
- • 5. Has a United States address as permanent residence
- Early Psychosis Participants:
- • 6. Diagnosis of one of the following conditions (confirmed via interview): schizophrenia; schizoaffective disorder; schizophreniform disorder; Psychosis not otherwise specified (NOS); major depressive disorder with psychotic features; bipolar disorder with psychotic features
- • 7. Willing to share contact with a clinical provider
- • EXCLUSION CRITERIA
- All participants:
- • 1. History of severe substance use in the past 3 months (determined by interview)
- • 2. Unable to demonstrate capacity to consent to research, in the judgment of the study team
- • 3. Diagnosed with a neurological disorder
- • 4. Previous clinically significant head injury or prolonged unconsciousness
- • 5. Significant cognitive training experience in the past 6 months
- • 6. Meets criteria for clinical risk of suicidal behavior.
- Non-Psychosis participants:
- • 7. Meets DSM-5 criteria for a psychotic, bipolar, or autism spectrum disorder
- • 8. Has a family history (1st degree relative) of psychosis, bipolar, or autism spectrum disorders
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Caroline Demro, PhD
Principal Investigator
University of Minnesota Department of Psychiatry and Behavioral Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials